Urogenital Atrophy

Urogenital Atrophy - Estrogen's Adieu

• Definition (GSM): Genitourinary Syndrome of Menopause: collection of symptoms/signs from $\downarrow$ estrogen & other sex steroid changes affecting labia, clitoris, vestibule/introitus, vagina, urethra, bladder.
• Epidemiology: Affects up to 50-70% of postmenopausal women; often underreported and undertreated.
• Pathophysiology: Estrogen decline $\rightarrow$
  • Thinned vaginal epithelium: $\downarrow$ glycogen, $\downarrow$ superficial cells, $\uparrow$ parabasal cells.
  • $\downarrow$ Collagen & elastin, $\downarrow$ vascularity.
  • $\uparrow$ Vaginal pH (>5.0).
  • Altered vaginal microbiota: $\downarrow$ Lactobacilli.
• Urinary Tract Effects: Similar atrophic changes in urethra and bladder trigone $\rightarrow$ urgency, dysuria, recurrent UTIs.

⭐ GSM is preferred over 'vulvovaginal atrophy' or 'atrophic vaginitis' as it better reflects the full spectrum of genitourinary involvement.

Clinical Features - Dry Spells & Drips

📌 Mnemonic: SAD LIPS (Sexual dysfunction, Atrophy, Dryness, Lubrication decrease, Itching, Pain, Soreness).

• Symptoms:
  • Genital: Dryness (most common), burning, irritation, itching, dyspareunia (superficial/entry), postcoital bleeding.
  • Urinary (LUTs): Dysuria, frequency, urgency, nocturia, recurrent UTIs, stress incontinence (may worsen).
  • Sexual: ↓ lubrication, pain/discomfort, arousal difficulties, ↓ libido (often secondary).

⭐ Dyspareunia is a hallmark symptom of GSM, significantly impacting quality of life.

• Signs on Examination:
  • Vulva: Loss of labial fat/turgor, sparse pubic hair, introital stenosis/narrowing.
  • Vagina: Pale, dry, smooth (loss of rugae) mucosa; friability, petechiae; prominent parabasal cells on wet mount.
  • Urethra: Urethral caruncle, eversion, prolapse; meatal tenderness. oka

Diagnosis & Differentials - Spotting the Signs

• Clinical: Symptoms (dryness, dyspareunia, urinary) + signs (pale, thin mucosa) in postmenopausal women (not on ET).
• Supportive Tests (often not needed):
  • Vaginal pH: > 5.0 (Normal premenopausal: $3.5-4.5$)
  • Vaginal Maturation Index (VMI): <5% superficial cells, ↑parabasal cells.
  • Wet Mount: Rules out infection; shows ↑WBCs, ↑parabasal cells.
  • Urine culture: If UTI symptoms.

⭐ A vaginal pH > 5.0 in a postmenopausal woman is highly suggestive of Genitourinary Syndrome of Menopause (GSM).

Differential Diagnoses (DDx):

• Infections: Candidiasis, Bacterial Vaginosis (BV), Trichomoniasis.
• Dermatoses: Lichen sclerosus, Lichen planus, Eczema.
• Irritant/Allergic dermatitis.
• Vulvodynia/Vestibulodynia.
• Desquamative Inflammatory Vaginitis (DIV).
• Neoplasia (VIN, VaIN; rare, persistent/atypical symptoms).

Management - Oasis Restoration

Goals: Relieve symptoms, restore urogenital physiology, improve Quality of Life (QoL).

• Non-Hormonal (First-line for mild symptoms):
  • Vaginal moisturizers: Regular use (e.g., polycarbophil, hyaluronic acid).
  • Vaginal lubricants: Coitally/as needed (water, silicone, oil-based).
  • Lifestyle: Continued sexual activity, avoid irritants, pelvic floor PT.
• Hormonal Therapy (Most effective for moderate-severe GSM):
  • Local Estrogen Therapy (LET) - Preferred for isolated GSM:
    • Forms: Creams (conjugated estrogens 0.625mg/g, estradiol 0.01%), tablets (estradiol 10mcg, 4mcg), rings (estradiol 7.5mcg/day).
    • Dosing: Initial daily for 1-2 weeks, then maintenance 2-3 times/week. (e.g., Estradiol 10mcg vaginal tablet).
    • Minimal systemic absorption; progestin generally NOT required with low-dose LET (uterus intact).
  • Systemic Estrogen Therapy (ET/HT): If concomitant vasomotor symptoms. Requires progestin if uterus intact.
• Other FDA-Approved Therapies:
  • Ospemifene: Oral SERM (60mg daily). Estrogen agonist on vagina. Risks: hot flushes, VTE.
  • Prasterone (Intrarosa®): Intravaginal DHEA (6.5mg daily). Local conversion.
• Emerging: Laser (CO2, Er:YAG), Radiofrequency - evidence evolving.

⭐ Low-dose vaginal estrogen therapy is the gold standard for symptomatic GSM and has an excellent safety profile with minimal systemic absorption.

High‑Yield Points - ⚡ Biggest Takeaways

• Urogenital atrophy (UGA), also known as Genitourinary Syndrome of Menopause (GSM), is primarily caused by estrogen deficiency post-menopause.
• Common symptoms include vaginal dryness, dyspareunia, pruritus, urinary urgency, dysuria, and recurrent UTIs.
• Clinical signs: pale, thin, dry vaginal mucosa, loss of rugae, and petechiae.
• Vaginal pH is elevated (typically > 5.0), reflecting altered flora.
• Microscopy shows an increased proportion of parabasal cells and a decrease in superficial cells.
• First-line treatment is low-dose topical estrogen; vaginal moisturizers and lubricants offer symptomatic relief.
• It is a chronic and progressive condition if left untreated, significantly impacting quality of life.